In addition, this approach of MSV/siRNA was validated in treating breast cancer by delivering siRNA-targeting ataxia telangiectasia mutated (ATM) genes using liposomes [78] or by modifying the surface of MSV with polyethyleneimine to form nanocomplexes within the pores to deliver ATM [79], STAT3, and GRP78 siRNA [80] inducing significant reduction in cancer stem cells. This evidence concerns the gene ATM and breast carcinoma.